Kymera Investor Presentation Deck

DL3 and 4 Degradation Profile of IRAK4, Ikaros and Aiolos Consistent with Strong Antitumor Activity in Preclinical Models IRAK4 Ikaros Aiolos Percent Change from Baseline Percent Change from Baseline 150 100 50 0 -50 -100 0 -20- -40 -60 -80 -100 150 100 50 -50 Target Degradation in PBMC by FLOW DL1 DL2 DL3 0.16 mg/kg 0.32 mg/kg 0.51 mg/kg Cycle 1 -100 T 0 0 T 2 24 Hours T 2 24 Hours 02 24 Hours Note Cycle 1, 72 hours window = +24 hours 72 72 Cycle 2 M 72 T 8 Days 8 + 15 0 15 Days - T 2 Hours DL4 0.82 mg/kg T T T 24 8 15 Days T T 0 2 24 8 15 Hours Days 8 15 0 2 24 8 15 Days Hours Days KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC. Dose Level DL1 DL2 DL3 DL4 Dose Level DL1 D DL3 DL4 Dose Level DL1 DL2 DL3 DL4 Cycle 1 -4% -28% ΝΑ -70% Cycle 1 -82% -92% ΝΑ -89% Cycle 1 -95% -100% ΝΑ -95% Cycle 2 0 -40% -57% ΝΑ Cycle 2 -89% -95% -96% ΝΑ Cycle 2 - 89% -100% -100% ΝΑ ● • Five patients were treated across DL1-4.* ● ● 1 each at DL1-3 and 2 at DL4 • PD results on first 4 patients Up to 70% KD of IRAK4 and 96- 100% KD of Ikaros and Aiolos in PBMC at DL1-4 • DL3-4 expected to be clinically active doses/profiles. Degradation consistent with target knockdown needed for antitumor responses in preclinical models of MYD88mut DLBCL (slide 36) * These included patients with transformed activated B-cell-like (ABC)-diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma, and plasmablastic lymphoma, all of whom were MYD88 wild-type except for one who had a MYD88 gain-of-function mutation. PAGE 39

View entire presentation